Beta Bionics has won FDA clearance for Mint, a tubeless insulin patch pump built around a reusable-and-disposable architecture that never needs recharging. The Irvine, California company announced the clearance on 14 September 2026 alongside a 510(k) submission for 3D Intelligence, the next generation of the dosing algorithm that runs its iLet Bionic Pancreas — and set a full U.S. launch for the first quarter of 2027.
The milestone
The clearance makes Beta Bionics the second company to bring a tubeless patch pump to the U.S. market, a category Insulet has held alone with Omnipod. According to the company’s announcement, Mint is a two-piece system: a reusable component and a disposable patch worn for three days plus a 12-hour grace period, holding a 200-unit reservoir, rated IPX8 waterproof to five feet for 60 minutes, and controlled from an iOS or Android phone. Disposable changes do not require re-pairing the phone.
On the same day the company filed a 510(k) for 3D Intelligence, an updated dosing algorithm offering three selectable modes — Original, Optimized and Conservative — that it intends to ship on both the existing iLet (as iLet 3D, targeted for the end of 2026) and on Mint (as Mint 3D, targeted for the first-quarter 2027 launch). Both remain subject to FDA clearance; the algorithm is not cleared today.
The technology
Beta Bionics built its business on the iLet Bionic Pancreas, an automated insulin delivery system whose adaptive closed-loop algorithm asks the user for body weight at setup and then doses without carbohydrate counting or manual basal rates. Mint takes that algorithm off the tubed pump and onto the body. Compatible sensors at clearance are Dexcom’s G7 and G7 15 Day and Abbott’s FreeStyle Libre 3 Plus; on the same morning, Senseonics announced a partnership to integrate its year-long implantable Eversense 365 CGM with the iLet, with commercial launch planned after integration work in the fourth quarter of 2026.
The company says Mint is smaller than the market-leading patch pump and, because the reusable half carries the electronics, the disposable half needs no battery to charge. Those are the company’s claims; head-to-head dimensions were not published in the release.
Why it matters
Patch pumps are where automated insulin delivery is growing fastest, and until now a prescriber choosing a tubeless system had one manufacturer to choose from. A second cleared platform — with a different algorithm philosophy and a pharmacy-channel model — changes the competitive map for endocrinology practices, payers and the CGM makers whose sensors these pumps depend on. Leerink Partners analyst Mike Kratky told MedTech Dive the clearance “should help level the playing field.”
For regulatory readers the sequencing is the instructive part: the hardware cleared first, and the algorithm that will differentiate it is on its own 510(k) track. Beta Bionics is therefore launching a cleared device while an uncleared software version is in review — a common pattern in automated insulin delivery, and one that keeps launch timing hostage to a second decision.
What comes next
- Full U.S. launch: first quarter of 2027, exclusively through the pharmacy channel, which the company says covers roughly 40% of insured U.S. lives at launch and is expected to reach at least 50% within the first year.
- Capacity: at least 1.5 million disposable Mint units planned for 2027.
- 3D Intelligence: 510(k) under review; iLet 3D targeted for the end of 2026 and Mint 3D for the Mint launch, both subject to clearance.
- Guidance: 2026 revenue guidance was revised to $121–126 million from $131–136 million, which the company attributed to prospective iLet users waiting for Mint.
What is not yet public: the cleared 510(k) number and the labelled age and diabetes-type indication for Mint, which the release does not state. FDA’s 510(k) database typically indexes a clearance within days; we will update this page when the record appears.
Sources & further reading
- Beta Bionics, “Beta Bionics Announces FDA Clearance of Mint™, the Company’s Transformative Patch Pump, and Unveils 3D Intelligence™ as its Next-Generation Insulin Dosing Algorithm,” press release, 14 September 2026. globenewswire.com
- Elise Reuter, “Beta Bionics’ insulin patch pump gets FDA nod,” MedTech Dive, 14 September 2026. medtechdive.com
- Senseonics, “Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense 365 with the iLet Bionic Pancreas,” press release, 14 September 2026. globenewswire.com
- Beta Bionics investor relations — news releases. investors.betabionics.com
Regulatory News reports on public regulatory documents. It is not legal advice, and the primary sources above govern. If we have made an error, we will say so in public: see corrections.
Frequently asked questions
What did FDA clear for Beta Bionics?
Mint, a tubeless insulin patch pump with a reusable component and a three-day disposable patch (plus a 12-hour grace period), a 200-unit reservoir, IPX8 waterproofing and smartphone control. The clearance was announced on 14 September 2026.
Is the 3D Intelligence algorithm cleared?
No. Beta Bionics submitted 3D Intelligence to FDA in a 510(k) on the same day. It plans iLet 3D by the end of 2026 and Mint 3D with the Mint launch in the first quarter of 2027, both subject to clearance.
When will Mint be available?
A full U.S. launch is planned for the first quarter of 2027, through the pharmacy channel only. The company plans capacity of at least 1.5 million disposable units in 2027.
Which CGMs work with Mint?
Dexcom G7, Dexcom G7 15 Day and Abbott FreeStyle Libre 3 Plus at clearance. Senseonics announced a separate integration of its Eversense 365 implantable sensor with the iLet.
